Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), is a single-stranded positive-sense ribonucleic acid (RNA) virus that typically undergoes one to two single nucleotide mutations per month. COVID-19 continues to spread globally, with case fatality and test positivity rates often linked to locally circulating strains of SARS-CoV-2. Furthermore, mutations in this virus, in particular those occurring in the spike protein (involved in the virus binding to the host epithelial cells) have potential implications in current vaccination efforts. In Rwanda, more than twenty thousand cases have been confirmed as of March 14th 2021, with a case fatality rate of 1.4% and test positivity rate of 2.3% while the recovery rate is at 91.9%. Rwanda started its genomic surveillance efforts, taking advantage of pre-existing research projects and partnerships, to ensure early detection of SARS-CoV-2 variants and to potentially contain the spread of variants of concern (VOC). As a result of this initiative, we here present 203 SARS-CoV-2 whole genome sequences analyzed from strains circulating in the country from May 2020 to February 2021. In particular, we report a shift in variant distribution towards the newly emerging sub-lineage A.23.1 that is currently dominating. Furthermore, we report the detection of the first Rwandan cases of the VOCs, B.1.1.7 and B.1.351, among incoming travelers tested at Kigali International Airport. We also discuss the potential impact of COVID-19 control measures established in the country to control the spread of the virus. To assess the importance of viral introductions from neighboring countries and local transmission, we exploit available individual travel history metadata to inform spatio-temporal phylogeographic inference, enabling us to take into account infections from unsampled locations during the time frame of interest. We uncover an important role of neighboring countries in seeding introductions into Rwanda, including those from which no genomic sequences are currently available or that no longer report positive cases. Our results point to the importance of systematically screening all incoming travelers, regardless of the origin of their travels, as well as regional collaborations for durable response to COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was commissioned by the National Institute of Health Research (NIHR) Global Health Research programme (16/136/33) using UK aid from the UK Government (funding to EM and NR through TIBA partnership) and additional funds from the Government of Rwanda through RBC/National Reference Laboratory in collaboration with the Belgian Development Agency (ENABEL) for additional genomic sequencing at GIGA Research Institute-Liege/Belgium. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, the National Institute of Health Research, the Department of Health and Social Care or the Rwandan Ministry of Health. GB acknowledges support from the Internal Fondsen KU Leuven/Internal Funds KU Leuven (Grant No. C14/18/094) and the Research Foundation Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, G0E1420N, G098321N). SLH acknowledges support from the Research Foundation/Flanders (Fonds voor Wetenschappelijk Onderzoek/ Vlaanderen, G0D5117N). SD is supported by the Fonds National de la Recherche Scientifique (FNRS, Belgium). VH was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/M010996/1]. A.OT is supported by the Wellcome Trust Hosts, Pathogens and Global Health Programme [grant number: grant.203783/Z/16/Z] and Fast Grants [award number: 2236]. AR acknowledges the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z ARTIC network) and the European Research Council (grant agreement no. 725422 ReservoirDOCS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Rwanda National Ethics Committee (FWA Assurance No. 00001973 IRB 00001497 of IORG0001100/15April2020) as well as the IRB of the University of Rwanda, College of Medicine and Health Sciences (Approval notice No 325/CMHS IRB/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available from the corresponding authors upon reasonable request.
